BARCELONA, Spain — A post hoc analysis of PULSAR trial data showed sustained fluid control at 2 years with fewer injections and longer dosing intervals in patients treated with aflibercept 8 mg for wet age-related macular degeneration.
“We also saw higher proportions of patients with fluid resolution observed with 8 mg vs. 2 mg when we assessed fluid 8 weeks after each active matched injection, starting from the third injection,” Praveen J. Patel, MBBChir, MA, FRCOphth, MD(Res), said at the Euretina congress.
The trial met its primary outcome at week (Read more...)